Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$653M |
| 2 |
Amazon
AMZN
|
+$602M |
| 3 |
ExxonMobil
XOM
|
+$473M |
| 4 |
Tesla
TSLA
|
+$437M |
| 5 |
Starbucks
SBUX
|
+$380M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$511M |
| 2 |
Netflix
NFLX
|
+$427M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$397M |
| 4 |
Nike
NKE
|
+$373M |
| 5 |
Microsoft
MSFT
|
+$365M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.68% |
| 2 | Healthcare | 17.69% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Industrials | 7.96% |
| 5 | Consumer Staples | 7.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2326
iShares US Consumer Staples ETF
IYK
$1.41B
| $1.13M | ﹤0.01% |
+17,700
| New | +$1.1M |
|
2327
Atossa Therapeutics
ATOS
$24.1M
| $1.13M | ﹤0.01% |
85,618
+2,793
| +3% | +$30.1K |
|
2328
Community Health Systems
CYH
$416M
| $1.13M | ﹤0.01% |
360,900
+307,773
| +579% | +$830K |
|
2329
State Street SPDR Portfolio S&P 400 Mid Cap ETF
SPMD
$18.6B
| $1.13M | ﹤0.01% |
23,200
+11,100
| +92% | +$495K |
|
2330
Larimar Therapeutics
LRMR
$436M
| $1.12M | ﹤0.01% |
247,042
+1,700
| +0.7% | +$5.74K |
|
2331
Children's Place
PLCE
$58.9M
| $1.12M | ﹤0.01% |
48,360
-84,100
| -63% | -$2.05M |
|
2332
Carter Bankshares
CARE
$751M
| $1.12M | ﹤0.01% |
74,800
-4,200
| -5% | -$52.9K |
|
2333
Xponential Fitness
XPOF
$266M
| $1.12M | ﹤0.01% |
+86,900
| New | +$1.18M |
|
2334
iShares Fallen Angels USD Bond ETF
FALN
$1.62B
| $1.12M | ﹤0.01% |
+42,300
| New | +$1.07M |
|
2335
Neuropace
NPCE
$474M
| $1.12M | ﹤0.01% |
108,325
+64,040
| +145% | +$511K |
|
2336
Zevra Therapeutics
ZVRA
$702M
| $1.12M | ﹤0.01% |
170,500
+37,800
| +28% | +$177K |
|
2337
Epsilon Energy
EPSN
$170M
| $1.11M | ﹤0.01% |
219,300
-58,500
| -21% | -$312K |
|
2338
GSI Technology
GSIT
$254M
| $1.11M | ﹤0.01% |
421,607
-52,443
| -11% | -$132K |
|
|
PRPH
2339
DELISTED
ProPhase Labs
PRPH
| $1.11M | ﹤0.01% |
24,571
-3,830
| -13% | -$175K |
|
2340
LENSAR
LNSR
$70.5M
| $1.1M | ﹤0.01% |
314,438
+4,993
| +2% | +$12.4K |
|
2341
First Trust Nasdaq-100 Select Equal Weight ETF
QQEW
$1.79B
| $1.1M | ﹤0.01% |
9,400
+3,800
| +68% | +$409K |
|
2342
VanEck Rare Earth/Strategic Metals ETF
REMX
$2.13B
| $1.1M | ﹤0.01% |
+17,935
| New | +$1.06M |
|
2343
Greif
GEF
$5.07B
| $1.1M | ﹤0.01% |
16,800
-13,300
| -44% | -$877K |
|
|
GOGL
2344
DELISTED
Golden Ocean Group
GOGL
| $1.1M | ﹤0.01% |
112,854
-311,415
| -73% | -$2.59M |
|
2345
Reading International Class A
RDI
$35.2M
| $1.1M | ﹤0.01% |
576,690
-2,300
| -0.4% | -$4.4K |
|
|
THRX
2346
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $1.1M | ﹤0.01% |
271,600
+145,406
| +115% | +$444K |
|
2347
Agilon Health
AGL
$1.45B
| $1.1M | ﹤0.01% |
3,500
-16,412
| -82% | -$5.94M |
|
|
FOLD
2348
DELISTED
Amicus Therapeutics
FOLD
| $1.1M | ﹤0.01% |
77,400
-71,000
| -48% | -$806K |
|
|
SCWX
2349
DELISTED
SecureWorks Corp Class A Common Stock
SCWX
| $1.09M | ﹤0.01% |
148,340
+14,600
| +11% | +$87.8K |
|
|
GAN
2350
DELISTED
GAN Ltd
GAN
| $1.09M | ﹤0.01% |
692,027
+215,610
| +45% | +$287K |
|
Similar funds
Renaissance Technologies's Q4 2023 Portfolio in Review
As of Q4 2023, Renaissance Technologies held 4,318 positions worth $64.6B, up 10% from $58.7B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q4 2023 filing shows 702 new, 1,590 increased, 1,355 reduced and 633 closed positions. Its largest new stake was Amazon: 4,296,466 shares worth $653M. The largest sale was Berkshire Hathaway Class A, an estimated $511M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q4 2023 buy was Amazon: 4,296,466 shares worth $653M.
- Renaissance Technologies added most to Meta Platforms (Facebook) in Q4 2023, an estimated $653M increase.
- Renaissance Technologies's biggest Q4 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $511M.
- Renaissance Technologies fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $397M.
- Renaissance Technologies's ten largest holdings make up 12% of its $64.6B portfolio in Q4 2023.
- Renaissance Technologies opened 702 new positions and closed 633 in Q4 2023.
- Renaissance Technologies's portfolio value rose 10% quarter-over-quarter to $64.6B.
Based on Renaissance Technologies's 13F filing for Q4 2023, filed 13 Feb 2024.